ltraviolet related DNA-damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic®.
Completed
- Conditions
- /A
- Registration Number
- NL-OMON28786
- Lead Sponsor
- MC Utrecht, department of Dermatology:Dr. M.S. de Bruin-WellerDr. E.F. KnolProf. dr. C.A.F.M. Bruijnzeel-Koomen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Age from 18 years;
2. Atopic dermatitis according to the criteria of Hanifin and Rajka;
Exclusion Criteria
1. Patients with any known hypersensitivity to mycofenolic acid or other components of the formulation;
2. Oral immunosuppressive treatment in the last 6 weeks;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference between the percentage in repair of cyclobutane pyrimidine dimers (CPD's) before and after treatment with Myfortic is the primary study outcome.
- Secondary Outcome Measures
Name Time Method Secondary study outcomes are the atopic state before and after treatment with Myfortic®.